目的：探讨替罗非班应用于急性ST段抬高型心肌梗死（STEMI）患者行急诊经皮冠状动脉介入治疗（PCI）的疗效。方法将96例STEMI行急诊PCI术的患者随机分为观察组与对照组，各48例。两组均予以常规治疗，观察组加用替罗非班，比较两组的疗效。结果观察组术中无复流、术后急性以及亚急性血栓形成率均较对照组显著降低（P＜0.05）；两组出血事件发生率无明显差异（P＞0.05）；观察组心血管不良事件发生率为8.33%，显著低于对照组的20.83%（P＜0.05）。结论替罗非班应用于急性STEMI行急诊PCI治疗，可降低术中无复流以及术后血栓形成率，降低术后心血管不良事件风险，不增加出血风险，改善临床预后。%Objective To investigate the efifcacy of tiroifban in acute ST-segment elevation myocardial infarction (STEMI) patients treated with primary percutaneous coronary intervention (PCI). Methods 96 acute STEMI patients underwent PCI surgery were randomly divided into observation group and control group, 48 cases in each group. Both groups were treated with routine treatment, observation group received tiroifban, the efficacy of the two groups were compared. Results The no-reflow,post acute and subacute thrombosis rate in observation group was was signiifcantly lower than the control group (P<0.05), the hemorrhage events rate of the two groups was not signiifcantly different (P>0.05), the rate of adverse cardiovascular events in observation group was 8.33%, signiifcantly lower than the 20.83%in the control group (P<0.05). Conclusion Tiroifban in acute STEMI patients treated with PCI can reduce the intraoperative and postoperative thrombosis rate, reduce the risk of postoperative cardiovascular events, does not increase the risk of bleeding, can improve clinical outcomes.
展开▼
